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Abstract Eosinophil-derived neurotoxin (EDN) is one of the
four basic proteins stored in speci¢c eosinophil granules. Here
we demonstrate that EDN can also be detected at the surface of
granulocytes. Reduction of EDN membrane expression after
phosphatidylinositol-speci¢c phospholipase C treatment suggests
that a glycosylphosphatidylinositol (GPI) anchor is involved in
the membrane association of EDN. The presence of a GPI
anchor was con¢rmed by a lower expression of membrane
EDN on granulocytes from patients with paroxysmal nocturnal
hemoglobinuria which present cells lacking GPI anchor pro-
teins. Furthermore, metabolic labeling with GPI anchor compo-
nents supports biochemical evidence of GPI anchoring of EDN.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Eosinophil-derived neurotoxin (EDN) is one of the four
cationic proteins present in eosinophil granules. It is found
in the granule matrix as shown by immuno-electron micros-
copy [1]. EDN is also present in basophils and in granules of
neutrophils [2,3]. In various eosinophilic diseases, this protein
is detected in blood or in body £uids. Elevated EDN levels
have been measured in urine collected from patients with
Churg^Strauss syndrome, atopic asthma, or helminth diseases
[4^6], in tears collected from conjunctival allergic disorders [7],
in sera of patients with asthma [8], and in cerebrospinal £uid
of children with Baylisascaris procyonis encephalitis [9]. More-
over, EDN levels may provide information on eosinophil ac-
tivation in diseases. For example, urinary EDN is a useful
marker for atopic dermatitis activity [10] and the measure-
ment of EDN in feces may be used for evaluating disease
activity and predicting relapse in patients with in£ammatory
bowel disease [11].
EDN possesses neurotoxic activities exhibited in the Gor-
don phenomenon [12] and exerts an inhibitory e¡ect on lym-
phocyte proliferation [13]. EDN has a weak helminthotoxic
activity as revealed by high concentrations needed to kill mi-
cro¢lariae of Bruga malayi or B. pahangi [14]. EDN has been
implicated in host defense against respiratory virus pathogens
via its ribonucleolytic activity [15,16]. Indeed, EDN presents a
strong structural homology with proteins of the ribonuclease
superfamily [17]. Recombinant EDN promotes a decrease in
respiratory syncytial virus infectivity that correlates with the
loss of viral genomic RNA, suggesting that EDN is respon-
sible for the direct ribonucleolytic destruction of extracellular
virus [15]. The mechanisms and the conditions of eosinophil
activation in which the ribonuclease enzymatic activity of
EDN is exhibited remain to be investigated.
Until now, EDN has been described as a protein stored in
the large cytoplasmic granules of granulocytes and secreted
after activation. In this study, we demonstrate that EDN is
also present on the eosinophil and neutrophil membranes as a
glycosylphosphatidylinositol (GPI)-anchored protein.
2. Materials and methods
2.1. Puri¢cation of peripheral blood cells
Human venous blood samples were obtained from seven healthy
donors, four hypereosinophilic patients and three patients with par-
oxysmal nocturnal hemoglobinuria (PNH) after written consent.
Mononuclear cells (MNC) and granulocytes were collected after cen-
trifugation on Ficoll-Paque (Tech Gen International, Les Ulis,
France). MNC were obtained from the interface and granulocytes
were depleted of erythrocytes by lysis, successively with 0.2% NaCl
and 1.6% NaCl. Granulocytes, collected from seven healthy donors
and three PNH patients, contained more than 95% neutrophils as
evaluated with a variant of the May-Gru«nwald-Giemsa method
(RAL kit, Vasse Industries, Paris, France). Eosinophils were puri¢ed
from three healthy subjects and four hypereosinophilic patients by
using a negative selection technique with CD16 antibody (Ab). Gran-
ulocytes were subjected to a magnetic cell separation system using
CD16 Ab conjugated with magnetic beads (Variomacs; Miltenyi Bio-
tec, Bergisch Gladbach, Germany), as described by Hansel et al. [18].
The degree of eosinophil purity evaluated with RAL kit was greater
than 95% (MNC were the predominant contaminating cells).
2.2. Puri¢cation of EDN and preparation of polyclonal anti-EDN
antibody
EDN was puri¢ed from urine of patients with blood hypereosino-
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philia according to a protocol described previously [19]. Polyclonal
anti-EDN Ab was obtained by immunization of rabbits, which were
inoculated with 200 Wg of puri¢ed EDN as 30 intradermal injections
in complete Freund’s adjuvant, according to Va|«kutakis [20]. Total
IgG from pooled sera of immunized rabbits was puri¢ed after incu-
bation with acrylic beads coupled with protein A (Sigma, Saint Louis,
MO, USA). Anti-EDN polyclonal IgG Ab fraction (anti-EDN Ab)
was diluted at a 1:1 ratio with glycerol (Sigma) and stored at 320‡C
until use. IgG fraction, prepared with the same procedure from non-
immunized rabbit sera (control Ab), was used as negative control.
2.3. Flow cytometry analysis
Cells (3U105) in 50 Wl of phosphate-bu¡ered saline (PBS) contain-
ing 1 mg/ml human Q-globulins (Sigma) were ¢rst incubated with
rabbit anti-EDN Ab or control Ab used at 1:20 dilution for 30 min
at 4‡C. After two washes with PBS, cells were incubated with FITC-
labeled goat F(abP)2 anti-rabbit IgG antibody (Pharmingen BD Bio-
sciences, San Diego, CA, USA) for 30 min at 4‡C and then washed
twice with PBS. Cells were analyzed using a £ow cytometer (Elite
ESP1, Beckman Coulter, Brea, CA, USA). To gate in lymphocyte
or monocyte population, 3U105 MNC were incubated with FITC-
conjugated CD3 or CD14 Ab (Beckman Coulter), respectively.
CD16, CD15 or CD11b expression was investigated using FITC-con-
jugated CD16 or CD15 Ab (Beckman Coulter) and PE-labeled
CD11b Ab (Dako, Glostrup, Denmark). Results were expressed either
as percentage of positive cells, determined by subtraction of binding
of unrelated rabbit or mouse antibodies, or as mean £uorescence
intensity.
To investigate the presence of GPI-anchored protein, granulocytes
were pre-incubated with phosphatidylinositol-speci¢c phospholipase C
(PI-PLC) derived from Bacillus cereus (0.01^1 U/ml) (Calbiochem,
San Diego, CA, USA) in RPMI 1640 for 1 h at 37‡C. Cells were
then washed twice with PBS, and stained for £ow cytometric analysis
as described above.
2.4. Immunostaining
Granulocytes and MNC (0.8U105), collected from healthy subjects,
were resuspended in 100 Wl of PBS, loaded on slides by cytocentrifu-
gation (Thermo Shandon, UK) and ¢xed for 20 min with 4% para-
formaldehyde at room temperature. After three washes, the prepara-
tions were incubated for 1 h, at room temperature, with rabbit anti-
EDN Ab or control Ab, diluted 1:1000 with Tris^HCl (0.05 M, pH 7)
containing human Q-globulins (1 mg/ml). After three washes, binding
of antibodies was detected by incubating cells with alkaline phospha-
tase-goat anti-rabbit IgG (dilution 1:1000; Sigma) for 1 h. Slides were
then developed with BCIP/NBT (Sigma).
2.5. Sandwich-ELISA EDN
Rabbit anti-EDN Ab was used to evaluate plasma EDN levels (ng/
ml) by using a sandwich ELISA as described previously [7]. Plasma
samples were tested in duplicate, at a dilution of 1:100 or 1:500.
2.6. Western blotting analysis
Cells were centrifuged 5 min at 300Ug and extraction bu¡er (20
mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 20% glycerol,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl £uoride, 5 Wg/ml
leupeptin, 5 Wg/ml aprotinin and 100 mM vanadate, Sigma) was added
to the pellet (10 Wl per 1U106 cells). After six freeze^thaw cycles,
tubes were centrifuged at 10 000Ug, 15 min at 4‡C. Supernatants,
containing nuclear and cytosolic proteins, were removed carefully
and kept at 380‡C until use. Protein extracts (20 Wg) or puri¢ed
EDN (1 Wg) were applied to a 12% SDS^polyacrylamide gel and
electro-transferred to nitrocellulose membrane. EDN was detected
by successive incubations with rabbit anti-EDN Ab (1:2500) and
then with peroxidase-coupled donkey anti-rabbit IgG (1:10 000)
(Amersham Biosciences, Buckinghamshire, UK). Immunoreactivity
was determined after incubation with the enhanced chemilumines-
cence detection reagents (ECL, Amersham Biosciences).
2.7. Metabolic labeling of neutrophils and immunoprecipitation
Peripheral blood neutrophils were incubated for 4 h at 37‡C with
0.5 mCi [9,10(n)-3H]palmitic acid or with 0.5 mCi [9,10(n)-3H]myristic
acid (Amersham Biosciences) coupled with serum albumin, in 10 ml
DMEM medium, or with 0.5 mCi [1-3H]ethan-1-ol-2-amine hydro-
chloride (Amersham Biosciences) in 10 ml DMEM medium, or with
0.5 mCi D-[6-3H]glucosamine hydrochloride (Moravek Biochemicals,
Brea, CA, USA) or with 0.5 mCi D-[2-3H]mannose (Amersham Bio-
sciences) in glucose-free DMEM medium (Invitrogen) supplemented
with 2.5 mM sodium pyruvate. After incubation, cells were washed
two times with PBS and the proteins were extracted with 1 ml of lysis
bu¡er (20 mM Tris, 140 mM NaCl, 1 mM EDTA, protease inhibitor
cocktail (Sigma), 1 mM iodoacetic acid (Sigma), 0.5% Triton X-100).
After 30 min on ice, tubes were centrifuged at 10 000Ug, 15 min at
4‡C. Supernatants were removed and speci¢cally immunoprecipitat-
ed overnight with 5 Wg rabbit anti-EDN Ab and 1 h with protein
G-Sepharose. Beads were eluted with Laemmli bu¡er [21] and samples
were subjected to a 12% SDS^polyacrylamide gel electrophoresis and
autoradiography analysis.
3. Results
3.1. Expression of EDN at the surface of human granulocytes
Detection of EDN was investigated using £ow cytometric
analysis at the surface of blood leukocytes. Monocytes, lym-
phocytes and neutrophils were collected from seven healthy
subjects whereas eosinophils were obtained from three healthy
subjects and four hypereosinophilic patients. The percentage
of EDN-positive cells was 79.5T 15.5% for neutrophils (Fig.
1A), 48.2 T 24.4% for eosinophils (Fig. 1B), 1.1 T 1.7% for
CD14-positive MNC (Fig. 1C), and 2.1 T 3.3% for CD3-pos-
itive MNC (Fig. 1D). Similar variations in the intensity of
surface expression of EDN with regard to cell speci¢city
were noted (mean £uorescence intensity: neutrophils : 16.9 T
22.3, eosinophils : 7.5 T 8, CD14-positive MNC: 0.5 T 0.1, and
CD3-positive MNC: 0.2 T 0.1). In agreement with results ob-
served by £ow cytometry analysis, high expression of EDN at
the surface of granulocytes was also revealed after immuno-
staining performed on cytopreparations of polymorphonu-
clear cells (Fig. 1G). In contrast, no staining was noted on
MNC, as shown in Fig. 1H.
3.2. EDN is present on the surface of cells that synthesize
the protein
To understand the origin of the membrane EDN, we exam-
ined if there was a correlation between eosinophil surface
EDN and plasma EDN levels that have been found to be
elevated in hypereosinophilic diseases. As shown in Table 1,
high or low EDN surface expression was observed on eosin-
ophils collected either in patients or in healthy donors. No
Table 1
Blood eosinophil counts, plasma EDN levels, and membrane EDN expression on eosinophils collected from healthy donors and from hypereo-
sinophilic patients
Healthy donors Hypereosinophilic patients
1 2 3 1 2 3 4
Blood eosinophil count (U109/l) 0.2 0.4 0.4 6.2 2.6 2.4 2.7
Plasma EDN levels (ng/ml) 20 60 78 631 736 200 390
EDN-positive eosinophils (%) 60.5 32.2 90.7 59.4 17.5 22.2 46.5
EDN surface expression is independent of the plasma EDN level.
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statistical di¡erence was noted between the percentage of
EDN-positive eosinophils from healthy and hypereosinophilic
patients (P=0.1, non-parametric Mann^Whitney test). EDN
surface expression appears to be independent of the plasma
EDN level (R=30.5, P=0.13, Spearman’s correlation test).
One possibility was that membrane EDN had an intracellular
origin. We tested this hypothesis by evaluating EDN synthesis
with Western blot analysis. As shown in Fig. 2, expression of
EDN was observed in neutrophils and eosinophils but not in
MNC. These data indicate that membrane EDN is detected
on cell populations that synthesize EDN protein.
3.3. Low EDN expression on the surface of cells isolated from
PNH patients
Next, we investigated how EDN could be linked to the
plasma membrane. Analysis of the EDN amino acid sequence
[22] does not suggest that EDN is a transmembrane protein,
since a sequence of about 26 hydrophobic amino acids re-
quired for transmembrane anchor is not found either in the
C-terminal or in the N-terminal EDN sequence. However, the
hydrophobicity pro¢le of the COOH-terminus published
EDN sequence [22] reveals that the end of the polypeptide
sequence is a short hydrophobic domain (residues 125^134)
preceded by 13 hydrophilic residues. Similar structure and
hydrophobicity pro¢le are shared with GPI-anchored proteins
[23].
To determine the involvement of a GPI anchor in the mem-
brane association of EDN, we evaluated the presence of EDN
Fig. 1. Membrane EDN is expressed on neutrophils and eosinophils but not on monocytes and lymphocytes. Cells were ¢rst incubated with
rabbit anti-EDN Ab (dotted line) or control Ab (solid line) in presence of human Q-globulins, then stained with FITC-labeled F(abP)2 fragment
of goat anti-rabbit IgG Ab. Surface expression of EDN on neutrophils (A), eosinophils (B), monocytes (C) gated with FITC-conjugated CD14
Ab, and on lymphocytes (D) gated with FITC-CD3 Ab was analyzed by £ow cytometry. Histograms are representative of each cell population
tested in one healthy subject. Cytocentrifuged polymorphonuclear (E,G) and mononuclear (F,H) cells were ¢xed with paraformaldehyde and in-
cubated with control Ab (E,F) or rabbit anti-EDN Ab (G,H) in the presence of human Q-globulins. The binding is revealed by alkaline phos-
phatase-goat anti-rabbit IgG Ab and BCIP/NBT.
Fig. 2. EDN is expressed in polymorphonuclear eosinophils (PNE)
and in polymorphonuclear neutrophils (PNN) but not in MNC.
Western blotting of 20 Wg of protein extracts probed with rabbit
anti-EDN Ab. The positive control contains 1 Wg of puri¢ed EDN
(lane EDN).
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on granulocytes isolated from patients with PNH. PNH is an
acquired defect of hematopoietic precursor cells in the biosyn-
thesis of the GPI anchor and may a¡ect clone progeny in the
di¡erent hematopoietic lineages. Membrane EDN expression
together with CD11b expression (a non-GPI-linked protein)
were investigated on neutrophils isolated from PNH patients
with 10%, 40% and 95% abnormal cells and from control
subject in comparison with CD16-1 (a GPI-anchored pro-
tein)/CD11b expression. As shown in Fig. 3A, neutrophils
from the control subject presented high density EDN expres-
sion. In PNH patients, we observed that high density EDN
expression shifted into low density EDN expression, accord-
ing to the extent of de¢ciency in the abnormal clone of these
PNH patients. The percentages of cells in the rectilinear re-
gion 2 are 6.5%, 40% and 75% for patients having 10%, 40%
and 95% abnormal cells, respectively. Similar shifts of CD16-1
expression were observed on granulocytes from the PNH pa-
tient having 95% abnormal cells (Fig. 3B). No variation in
CD11b expression was observed on cells from either healthy
or PNH subjects.
3.4. Membrane EDN expression is sensitive to PI-PLC
treatment
To back up the results, we evaluated by £ow cytometric
analysis the EDN expression on neutrophils treated with PI-
PLC. The e¡ect of hydrolysis induced by PI-PLC on EDN
membrane expression was compared to the e¡ect on the car-
bohydrate CD15 antigen, which is not GPI-anchored, and to
the expression of CD16-1 antigen, a GPI-anchored protein
[24]. PI-PLC treatment at 0.1 U/ml (Fig. 4) induced a drastic
Fig. 3. Membrane EDN expression parallels the percentage of ab-
normal cells isolated from PNH patients. Neutrophils isolated from
one representative healthy control and from three PNH patients
having 10%, 40% and 95% abnormal cells. Double staining with
PE-CD11b Ab and rabbit anti-EDN Ab with FITC-goat anti-rabbit
IgG (A). Double staining with PE-CD11b Ab and FITC-CD16 Ab
(B). Two quad-stat regions were placed in each graph. Quad-stat re-
gion 1 separates negative cells for CD11b and EDN expression (de-
termined with corresponding unrelated Ab) and the vertical line of
quad-stat 3 is placed at the lowest value of the £uorescence intensity
of EDN-positive cells from the healthy control sample. The rectilin-
ear region 2 corresponds to CD11b-positive cells with low expres-
sion of EDN.
Fig. 4. Modulation of EDN membrane expression after treatment
with PI-PLC. Respective numbers of CD15- CD16-, and EDN-posi-
tive cells were evaluated with (thick line) and without (dotted line)
treatment with PI-PLC (0.1 U/ml) (thin line: control Ab). Histo-
grams illustrate one representative experiment.
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decrease in the intensity of £uorescence on EDN-positive cells
(reduction of 56.5 T 15.8%, n=4) and on CD16-positive cells
(reduction of 59.5 T 18.5%, n=4), while CD15 expression was
unchanged. A higher concentration of PI-PLC (1 U/ml) was
not more e¡ective in EDN release from the membrane (not
shown).
3.5. EDN is linked to the membrane through a GPI anchor
molecule
To demonstrate that EDN is directly linked to a GPI an-
chor we performed metabolic labeling of neutrophils with tri-
tiated GPI anchor components such as ethanolamine, glucos-
amine, mannose, myristic acid, and palmitic acid. After
immunoprecipitation with rabbit anti-EDN Ab, proteins ex-
tracts were subjected to SDS^PAGE and autoradiography.
We obtained a band corresponding to the size of EDN but
with various intensities, depending on the labeling. In Fig. 5A
the amount of incorporated radioactivity was 12 000 cpm with
[3H]palmitic acid (lane 1), 5300 cpm with [3H]glucosamine
(lane 2), 1700 cpm with [3H]mannose (lane 3), and 2800
cpm with [3H]ethanolamine (lane 4). Labeling of neutrophils
with [3H]myristic acid did not result in incorporation of radio-
activity into EDN (not shown). Coomassie blue staining of
the gel showed that the same amounts of proteins were loaded
on each lane (Fig. 5B). No signal was obtained after immu-
noprecipitation with the control rabbit serum of cell extract
labeled with [3H]palmitic acid (Fig. 5A, lane 5). Taken togeth-
er with the PI-PLC assay, these results show that the mem-
brane association of EDN on granulocytes involves a GPI
anchor.
4. Discussion
EDN is a cationic protein known to be present in granules
of eosinophils and neutrophils. Our results indicate that EDN
can be detected at the surface of neutrophils and eosinophils
as revealed by £ow cytometric analysis and immunostaining
using rabbit polyclonal anti-EDN Ab. This antibody is spe-
ci¢c for EDN and recognizes a 18 kDa protein in urine of
hypereosinophilic patients as well as in eosinophils and neu-
trophils, revealed by Western blot analysis. Moreover, in the
sandwich ELISA EDN, this antibody does not cross-react
with ECP, the most closely related protein. Numerous immu-
nochemical studies have already been performed on eosino-
phils to detect the presence of intracellular EDN. Staining was
usually preceded by a cell permeabilization step that altered
the plasma membrane, leading to a release of endogenous PI-
PLC [25]. This procedure may explain why EDN has not yet
been detected as a membrane protein. Here we used parafor-
maldehyde-¢xed cells that keep the integrity of their plasma
membrane.
Absence of transmembrane anchor sequence and hydropho-
bicity pro¢le of the COOH-terminus published EDN sequence
led us to investigate the presence of EDN at the surface of
granulocytes collected from patients with PNH, an acquired
defect of hematopoietic precursor cells in the biosynthesis of
GPI. A cell population with very low density expression of
EDN was detected and its extent paralleled those of abnormal
clones detected with other GPI-anchored molecules: CD16 on
neutrophils and CD14, CD66 on monocytes (not shown). The
cleavage of GPI anchors by bacterial PI-PLC is the most
common criterion used in GPI anchor identi¢cation. The re-
lease of EDN from the membrane is induced by PI-PLC up to
about 60%. Cleavage to a similar extent is described for other
GPI-anchored proteins [26,27]. The sensitivity of GPI-an-
chored proteins towards PI-PLC is dependent on the speci¢c-
ity of the cells tested [28], the lipid £uidity of the membrane
[27], and the origin of the phospholipase [29]. The sensitivity
of neutrophil membrane EDN might be related to the proper-
ties of PI-PLC obtained from B. cereus used in our experi-
ments. In spite of the low metabolism of the di¡erentiated
cells, metabolic labeling of neutrophils with components com-
mon to all GPI molecules was successful. Together with the
cleavage by PI-PLC, the incorporation of radioactivity shows
that a GPI anchor is involved in the membrane association of
EDN. Alternative splicing is a mechanism known to generate
transmembrane, GPI-anchored, or secreted forms of several
proteins [30,31]. An alternative splicing could explain the pres-
ence of a membrane EDN isoform containing a GPI anchor,
and of a granule EDN isoform susceptible to be secreted.
An alternatively spliced mRNA of VCAM leads to a GPI-
anchored protein [32] detected by incorporation of [3H]-
ethanolamine and by cleavage of VCAM after PI-PLC treat-
ment. In the case of EDN, we have found incorporation of
radioactivity after labeling with [3H]ethanolamine, [3H]pal-
mitic acid, [3H]glucosamine, and [3H]mannose.
These new ¢ndings raise questions about the physiopatho-
logic functions of EDN on the surface of polymorphonuclear
cells. EDN is mainly described as a protein with ribonuclease
activity. Domachowske and colleagues have demonstrated
that eosinophils are capable of inhibiting retroviral transduc-
tion of human target cells [33]. Puri¢ed EDN has been shown
to exert this antiviral activity [15,16] that is speci¢cally
blocked by a ribonucleolytically inactivated mutant of EDN
[34]. In this context, it would be of interest to evaluate the role
of surface EDN. In the absence of eosinophil degranulation
Fig. 5. A GPI anchor is involved in the membrane association of
EDN. Autoradiography after metabolic labeling of neutrophils with
tritiated GPI anchor components (PA: [3H]palmitic acid, GlcN:
[3H]glucosamine, Man: [3H]mannose, EtN: [3H]ethanolamine), and
immunoprecipitation with anti-EDN Ab or control Ab (A). Coo-
massie blue staining of the SDS^PAGE (B).
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that releases the cationic proteins, EDN present at the surface
or cleaved by the action of speci¢c phospholipases on the GPI
anchor could directly exert this antiviral activity. Doma-
chowske et al. have obtained results suggesting that regions
within the ¢rst 50 amino acids of human EDN are required
for an antiviral activity [34]. With regard to the EDN se-
quence, one putative GPI binding site for EDN protein might
be found between the Cys 111 and Asp 112 amino acids since
the two amino acids found usually immediately after the GPI
binding site are combinations of A, N, D, G, and S residues
[35]. In this case, the N-terminal end is conserved leading to
the maintenance of enzyme activity. It would give one more
clue to support the idea of the implication of eosinophils in
the immune response in viral infections.
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